在牙科实践中接受抗凝治疗的患者的管理:系统性审查
Francesco Inchingolo1, Angelo Michele Inchingolo1, Fabio Piras1
1Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
Healthcare (Basel, Switzerland)
|August 9, 2024
概括
在牙科实践中对抗凝血药物的管理对于患者的安全至关重要. 局部止血措施和改善医疗保健专业人员的合作是减少抗凝剂治疗患者在牙科手术期间出血风险的关键.
科学领域:
- 口腔医学是指口腔医学.
- 药理学 药理学是指药理学的学科.
- 血栓形成的研究研究
背景情况:
- 抗凝剂药物对于预防高风险个体的血栓事件至关重要.
- 在日常牙科护理中,有效的抗凝药管理是必不可少的.
- 本文献综述侧重于牙科机构中抗凝剂管理的实际应用.
研究的目的:
- 审查当前关于在牙科手术期间治疗抗凝剂患者的管理文献.
- 确定最佳实践,以最大限度地降低该患者群体的出血风险.
- 突出牙科专业人员在安全地向服用抗凝药的患者提供牙科护理方面的作用.
主要方法:
- 使用PubMed,Scopus和Web of Science进行了全面的文献搜索.
- 包括1989年1月1日至2024年3月7日期间出版的英语文章.
- 搜索策略使用了布尔的关键词"抗凝剂和牙科".
主要成果:
- 在经过严格选后,从最初识别的623篇文章中选择了25项临床试验.
- 审查的研究主张使用局部止血剂控制抗凝药的牙科患者的出血.
- 调查结果强调需要加强医疗保健提供者之间的教育和专业间合作.
结论:
- 研究的进步已经完善了对抗凝血剂或抗血小板治疗患者的牙科程序的理解和管理.
- 有效的管理策略包括使用静血剂,遵守临床方案,并考虑个体风险因素.
- 医疗保健专业人员的持续教育对于确保最佳患者结果和福祉至关重要.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
657
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
502
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502
01:24Disorders of Hemostasis
768
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
768
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:26Tonsillitis II: Management
105
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
105